German psychedelics startup Atai makes splash with IPO, gaining 40% in U.S. debut
Shares of Atai Life Sciences B.V., backed by billionaire investor Peter Thiel, surged 40 per cent in their U.S. stock market debut on Friday, giving the German psychedelics startup a market capitalization of US$3.19 billion.
The Berlin-based biotech startup, which is exploring the use of psychedelic treatments for mental illnesses, raised US$225 million from selling 15 million shares in its upsized initial public offering (IPO) on Thursday.
The company's shares opened at US$21, higher than the IPO price of US$15, but gave up early gains to trade flat by 1600 GMT.
Atai was co-founded in 2018 by German investor Christian Angermayer, an advocate of the benefits of using psychedelics such as psilocybin to treat depression, anxiety and substance use disorders.
The German startup has backed several companies developing such therapies.
Psilocybin, the psychedelic active compound in magic mushrooms, was found to be at least as effective as escitalopram, a leading antidepressant drug, in a study by British scientists. Atai was considering floating its shares in the United States in May, Reuters reported in March, citing a source close to the matter.
Its debut comes at a time when U.S. IPOS have already raised US$171 billion in the first six months of the year, scorching past the 2020 record of US$168 billion, according to data from Dealogic.
Angermayer has backed about 30 biotech companies, including immunotherapies firm Sensei Biotherapeutics, mental health care company Compass Pathways and artificial intelligence-powered drug discovery platform Abcellera Biologics, all of which listed in the United States in recent months.
Germany-based laser communication technologies firm Mynaric and data centre operator Northern Data, both partially owned by Angermayer, are also planning to list on the Nasdaq later in 2021 or in 2022, Reuters reported on Thursday.
Credit Suisse, Citigroup, Cowen and Berenberg were the lead underwriters for the offering.